Senexin B
Senexin B (SNX2-1-165; BCD-115) is a potent, highly water-soluble and bioavailable CDK8/19 inhibitor, with Kds of 140 nM for CDK8 and 80 nM for CDK19.
Product Specifications
CAS Number
1449228-40-3
Product Name Alternative
SNX2-1-165; BCD-115
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
CDK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Senexin_B.html
Purity
99.09
Solubility
DMSO : 6 mg/mL (ultrasonic; warming) |H2O : < 0.1 mg/mL
Smiles
N#CC1=CC2=C(NCCC3=CC=C4C=C(C(N5CCN(C)CC5)=O)C=CC4=C3)N=CN=C2C=C1
Molecular Formula
C27H26N6O
Molecular Weight
450.53
Precautions
H302, H315, H319, H335
References & Citations
[1]Porter D, et al. Abstract PR08: Targeting tumor microenvironment with selective small-molecule inhibitors of CDK8/19. Abstracts: AACR Special Conference on Cellular Heterogeneity in the Tumor Microenvironment; 2014 Feb 26-Mar 1; San Diego, CA. Philadelphia (PA) : AACR; Cancer Res 2015;75 (1 Suppl) :Abstract nr PR08. doi:10.1158/1538-7445.CHTME14-PR08|[2]McDermott MS, et al. Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancer. Oncotarget. 2017 Feb 21;8 (8) :12558-12575.|[3]CDK8-CDK19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer. US 9321737 B2
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Isoform
CDK19; CDK8
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
135003-ML550 100 µL
UBE2L3 (Ubiquitin-conjugating Enzyme E2 L3, L-UBC, UBCE7, UbcH7, Ubiquitin Carrier Protein L3, Ubiquitin-conjugating Enzyme E2-F1, Ubiquitin-protein Ligase L3) (MaxLight 550)
Sign In for Pricing
View Details 